Maternal inflammation during pregnancy may be linked to a risk of schizophrenia in the woman’s offspring, according to a new study in The American Journal of Psychiatry based on analysis of data from a large Finnish cohort.
Maternal inflammation during pregnancy may be linked to a risk of schizophrenia in the woman’s offspring, according to a new study in TheAmerican Journal of Psychiatry based on analysis of data from a large Finnish cohort.
In the nested case-control study, researchers at Columbia University's Mailman School of Public Health, Columbia University Medical Center, and the New York State Psychiatric Institute identified 777 schizophrenia cases (schizophrenia, N = 630; schizoaffective disorder, N = 147) from the Finnish Prenatal Study of Schizophrenia cohort that also had maternal sera samples available for C-reactive protein testing and matched them with 777 control subjects. A latex immunoassay was used to assess maternal C-reactive protein levels in both groups.
Classified as a continuous variable, increasing maternal C-reactive protein levels were found to be significantly associated with schizophrenia in offspring (adjusted odds ratio=1.31, 95% confidence interval=1.10–1.56). Even after adjusting for potential confounders such as parental history of psychiatric disorders, twin/singleton birth, urbanicity, province of birth, and maternal socioeconomic status, the finding remained significant.
Investigators concluded that their results provide the most robust evidence so far that maternal inflammation may play a significant role in schizophrenia. This finding could have possible implications in identifying preventive strategies and pathogenic mechanisms in schizophrenia and other neurodevelopmental disorders.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Increase in ED visits for hypertensive disorders from 2006 to 2020 reported
September 18th 2024In a recent study, reported rates on emergency department utilization for hypertensive disorders of pregnancy and the postpartum period were higher in 2020 than 2006, with rates especially high among non-Hispanic Black, Hispanic, and Asian patients.
Read More
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More